GlobalResearch and clinical trials
Once-weekly growth hormone as effective as daily injections in Turner syndrome in a phase 3 trial
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
Once-weekly growth hormone was tested in girls with Turner syndrome. The phase 3 trial included 105 children from 18 countries. After one year, the rate of height growth was considered equivalent to that with daily injections. Side effects were similar in the two groups.
What does it mean for patients and families?
A once-weekly injection may reduce the treatment burden for children. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes. Treatment decisions are made with the doctor.
Source
Scientific paper: Once-weekly somapacitan enhances linear growth in girls with Turner syndrome: a randomized controlled phase 3 study. The Journal of Clinical Endocrinology and Metabolism, 2026. DOI: 10.1210/clinem/dgag309 · PubMed 42538806
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Turner syndrome
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.